Tonix Pharmaceuticals Reports First Quarter 2015 Financial Results and Clinical Update
May 11, 2015 06:00 ET
|
Tonix Pharmaceuticals Holding Corp.
On Track to Commence Two Clinical Studies This Quarter;
Phase 2 Proof-of-Concept Headache Study Results Due by Year-End
NEW YORK, May 11, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding...
Tonix Pharmaceuticals to Present at the 12th Annual BIO Asia International Conference
March 20, 2015 11:30 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, March 20, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a pharmaceutical company with clinical-stage development programs in fibromyalgia, post-traumatic stress...
Tonix Pharmaceuticals to Present at the 27th Annual ROTH Conference
March 04, 2015 08:40 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, March 4, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company, will present at the 27th Annual ROTH Conference to be held at...
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
March 03, 2015 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, March 3, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) announced financial results for the fourth quarter and full year ended December 31, 2014. Tonix filed its...
Tonix Pharmaceuticals to Present at the 8th Annual European Life Sciences CEO Forum
March 02, 2015 08:40 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, March 2, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the 8th Annual European Life Sciences CEO Forum & Exhibition in Zurich, Switzerland....
Tonix Pharmaceuticals Announces Closing of $28.7 Million Public Offering of Common Stock
February 09, 2015 13:45 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced the closing of its previously announced underwritten public offering of 4,900,000 shares of...
Tonix Pharmaceuticals to Present at the BIO CEO & Investor Conference
February 05, 2015 10:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the 17th Annual BIO CEO and Investor Conference in New York City. Seth Lederman, M.D.,...
Tonix Pharmaceuticals Prices Underwritten Public Offering of Common Stock
February 04, 2015 08:15 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Feb. 4, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced the pricing of an underwritten public offering of 4,900,000 shares of its common stock at a...
Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
February 03, 2015 16:02 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Feb. 3, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced that it intends to offer shares of its common stock in an underwritten public offering. The...
Tonix Pharmaceuticals Commences Phase 2 Trial of TNX-102 SL in Post-Traumatic Stress Disorder
January 15, 2015 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Jan. 15, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) announced today that the first participant in the AtEase study, sponsored by Tonix to evaluate TNX-102 SL...